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Abstract
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease characterized by lobular
inflammation, hepatocellular ballooning, and fibrosis with an inherent risk for progression to cirrhosis and hepatocellular
carcinoma (HCC). Mitochondrial dysfunction appears to play a role in the progression from simple steatosis to NASH. L-
carnitine (L-b-hydroxy-g-N-trimethylaminobutyric acid), an essential nutrient that converts fat into energy in mitochondria,
has been shown to ameliorate liver damage. The aim of the present study was to explore the preventive and therapeutic
effect of L-carnitine in NASH model mice. Eight-week-old male STAM mice, a NASH-cirrhosis-hepatocarcinogenic model,
were divided into 3 experimental groups and fed as follows: 1) high-fat diet (HFD) (control group); 2) HFD mixed with 0.28%
L-carnitine (L-carnitine group); and 3) HFD mixed with 0.01% a-tocopherol (a-tocopherol group). After 4 or 8 weeks, mice
were sacrificed. Blood samples and livers were collected, and hepatic tumors were counted and measured. Livers were
subjected to histological study, immunohistochemical staining of 4-hydroxynonenal and ferritin, determination of 8-OHdG
levels, mRNA and protein expressions for multiple genes, and metabolomic analysis. The intestinal microbiome was also
analyzed. L-carnitine increased hepatic expression of genes related to long-chain fatty acid transport, mitochondrial b-
oxidation, and antioxidant enzymes following suppression of hepatic oxidative stress markers and inflammatory cytokines in
NASH, and mice treated with L-carnitine developed fewer liver tumors. Although a-tocopherol resulted in NASH
improvement in the same manner as L-carnitine, it increased periodontitis-related microbiotic changes and hepatic iron
transport-related gene expression and led to less effective for anti-hepatocarcinogenesis.
Conclusion: L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model by upregulating the
mitochondrial b-oxidation and redox system.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common liver
disease that is characterized by hepatic steatosis. Most patients
with NAFLD exhibit non-progressive simple fatty liver, namely
non-alcoholic fatty liver. Non-alcoholic steatohepatitis (NASH) is a
more severe form of NAFLD that is characterized by lobular
inflammation, hepatocellular ballooning, and fibrosis with an
inherent risk for progression to cirrhosis and hepatocellular
carcinoma (HCC) [1]. These features were defined by Ludwig et
al. in 1980 to describe a liver disease that histologically mimics
alcoholic hepatitis but occurs in individuals who do not abuse
alcohol [2]. Because NASH can progress towards end-stage liver
disease requiring a liver transplant, therapies for NASH must be
developed. Even though the mechanisms of the progression from
simple steatosis to NASH are not completely understood,
accumulating evidence suggests a major role of mitochondrial
dysfunction in steatosis and steatohepatitis [3]. Mitochondrial
dysfunction not only impairs fat homeostasis in the liver but also
leads to an overproduction of oxidative stress-inducing reactive
oxygen species (ROS) that trigger lipid peroxidation, cytokine
overproduction, and cell death. Indeed, ultrastructural alterations,
impairment of adenosine triphosphate synthesis, and increased
production of ROS have been reported in liver mitochondria from
NASH patients and a rodent model [4,5].
Vitamin E supplementation, the prototypical antioxidant drug
treatment, has become a standard treatment for NASH [6].
However, most clinical studies of atherosclerotic diseases with
dietary antioxidants have not generated clear results, partly
because of the non-selective effects of these anti-oxidative drugs
[7]. Controversy surrounds antioxidant therapies because ROS
have essential functions in living organisms.
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L-carnitine (L-b-hydroxy-g-N-trimethylaminobutyric acid) is an
essential nutrient that converts fat into energy in mitochondria. It
acts as a carrier for fatty acid across the mitochondrial membrane
and is also present in the free or acyl-carnitine form in plasma
[8,9]. L-carnitine plays an important role in lipid metabolism; it
acts as an essential cofactor for the b-oxidation of fatty acids by
facilitating the transport of long-chain fatty acids (LCFAs). It can
activate carnitine palmitoyltransferase (Cpt), the key enzyme in
fatty acid oxidation [10]. Recently, L-carnitine has been proposed
for the treatment of various diseases, including liver injury. Several
studies have shown that L-carnitine administration can ameliorate
or prevent liver damage of various etiologies. Animal studies have
shown that dietary supplementation with L-carnitine prevents
hepatitis and subsequent HCC [11]. L-carnitine is not an oxidative
stress scavenger but it may stimulate mitochondrial function, and
the effect would be different from typical antioxidants. The aim of
the present study was to explore the preventive and therapeutic
effects of L-carnitine in NASH model mice in order to provide
evidence for L-carnitine as a treatment candidate for NASH.
Materials and Methods
Animals and experimental design
STAM mice, a NASH-cirrhosis-hepatocarcinogenic model,
were purchased from Stelic Institute & Co., Inc. (Tokyo, Japan).
This mouse model progresses from NAFLD to NASH at 8 weeks
of age and develops HCC at 16 weeks of age [12]. Briefly,
C57BL/6J male mice were injected with streptozotocin 2 days
after birth to destroy pancreatic beta cells, and were fed a high-fat
diet (HFD-32; CLEA-Japan, Tokyo, Japan).
For NASH experiments, 8-week-old male STAM mice were
divided into three experimental groups and fed for 4 weeks as
follows: 1) high-fat diet (HFD) (Control group); 2) HFD mixed with
0.28% L-carnitine (LKT Laboratories, Inc., St. Paul, MN, USA)
(L-carnitine group); and 3) HFD mixed with 0.01% a-tocopherol
(LKT Laboratories, Inc.) (a-tocopherol group). Diets were
replaced 3 times per week to keep them dry, as high fat diets
tend to retain moisture. After 4 weeks, mice were sacrificed. Blood
samples were obtained from the right atrium by cardiac puncture,
and the livers were excised. Livers were cut into pieces and fixed in
10% formalin for histological analysis, or fresh-frozen in liquid
nitrogen and stored at 280uC in a freezer until use. L-carnitine
and a-tocopherol concentrations were decided based on previous
reports, and were confirmed to show the same improvement in
histological activity and stage in our STAM mouse model [13,14].
For hepatocarcinogenesis experiments, 8-week-old STAM mice
were divided into three experimental groups and fed for 8 weeks as
described above. After 8 weeks, mice were sacrificed and hepatic
tumors were counted and measured.
Animals had free access to water and food and were maintained
under specific pathogen-free (SPF) conditions in a temperature-
controlled animal facility with a 12-h light-dark cycle. Cages
Figure 1. Body weight, plasma and hepatic biochemical levels. (A) Body weight of the three experimental groups. Eight-week-old male STAM
mice were divided into three experimental groups and fed for 4 weeks as follows: 1) high-fat diet (HFD) (control group); 2) HFD mixed with 0.28% L-
carnitine (L-carnitine group); and 3) HFD mixed with 0.01% a-tocopherol (a-tocopherol group). After 4 weeks, mice were weighed. (B) Fasting blood
glucose levels of the three experimental groups. (C) Plasma biochemical findings of experimental groups. (D) Hepatic triglyceride levels of
experimental groups. Data are expressed as mean 6 standard deviation (SD).
doi:10.1371/journal.pone.0100627.g001
L-Carnitine Prevents Progression of NASH in a Mouse Model
PLOS ONE | www.plosone.org 2 July 2014 | Volume 9 | Issue 7 | e100627
housed 4 mice and the bedding material was made from paper
rolls (Paper Clean; Peparlet Co., Ltd, Fujieda, Japan). All protocols
and procedures conformed to the guidelines of the Okayama
University Committee for Care and Use of Laboratory Animals
and were approved by the Animal Experiments Ethics Committee
of Okayama University.
Measurement of weight, fasting blood glucose, plasma
aminotransferases and triglycerides
Body weight of mice at sacrifice on week 12 after birth was a
median 19.9 g (interquartile range; 18.0–21.2 g). Fasting blood
glucose levels were measured with a blood glucose meter (GT-
1820; Arkray Inc., Kyoto, Japan). Alanine aminotransferase and
triglyceride levels were determined by standard methods at
Skylight Biotech Company (Akita, Japan).
Histological analysis of liver
Sections of formalin-fixed livers were stained with hematoxylin-
eosin. NAFLD activity was assessed by NAFLD activity score, as
described by Kleiner et al., with separate scores for steatosis (0–3),
hepatocellular ballooning (0–2), and lobular inflammation (0–3).
NAFLD activity score is the sum of these scores, and values of $5
are correlated with a diagnosis of NASH. All liver specimens were
assessed by two hepatologists (TY and AT) blinded to the identities
of the study groups.
Immunohistochemistry of oxidative damage marker and
ferritin
Immunohistochemical staining of 4-hydroxynonenal (4-HNE)
and ferritin was performed. Liver samples were fixed in 10%
formaldehyde. The sections were incubated with a 1:100 dilution
of primary antibody for 4-HNE (clone HNEJ-2; JaICA, Shizuoka,
Japan) at 4uC overnight. Subsequently, they were incubated with
secondary antibody (Dako: LSAB + System-HRP), universal
biotinylated link antibody, and streptavidin-HRP. Slides were
stained with fresh 3,39-diaminobenzidine chromogen (Dako,
Liquid diaminobenzidine + Substrate Chromogen System). For
ferritin staining, primary antibody (Abcam, Cambridge, UK) was
used at a 1:1000 dilution. Quantitative comparison of immuno-
histochemistry staining was performed by computerized image
analysis with Olympus cellSens imaging software (Olympus,
Tokyo, Japan).
Quantitative real-time polymerase chain reaction
Total RNA was prepared from liver tissue with TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA). Extracted RNA was converted
into cDNA by reverse transcription (SuperScript III Reverse
Transcriptase; Invitrogen). Specific gene expression was quantified
by real-time PCR performed on a LightCycler 480 Instrument
(Roche Diagnostics Ltd., Rotkreuz, Switzerland). Relative expres-
sion levels of target genes were compared after normalization
against b-actin. Tumor necrosis factor (TNF)-a expression was
determined with a LightCycler primer and probe set (Nihon Gene
Research Laboratories, Sendai, Japan). The following genes were
assessed with a SYBR green fluorophore: interleukin (IL)-1b,
organic cation/carnitine transporter (OCTN) 2, Cpt1a, Cpt2,
medium-chain acyl-CoA dehydrogenase (MCAD), superoxide
dismutase (Sod)2, catalase (CAT), glutathione peroxidase (Gpx)1,
Gpx4, divalent metal transporter 1 (DMT-1), and Hamp (hepcidin
coding gene).
Figure 2. Liver histological findings. (A) Representative H&E-stained liver sections are shown. (B) Non-alcoholic fatty liver disease activity scores
(NAS) for mouse liver specimens of the three experimental groups. Steatosis, inflammation, and hepatocyte ballooning were categorized, and the
sum of these scores was designated as NAS. Data are expressed as means 6 SD. *P,0.05.
doi:10.1371/journal.pone.0100627.g002
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Western blotting analysis
Total proteins were extracted from liver tissue using a protein
extraction kit (Minute Protein Extraction Kit; Invent Biotechnol-
ogies, Inc., Eden Prairie, MN, USA). Extracted proteins were
quantitated by the BCA method (BCA protein Assay Kit; Takara
Bio, Inc., Otsu, Japan), and were diluted to the same protein
concentrations. Equivalent amounts (50 mg) of each group were
run on SDS polyacrylamide gels. Proteins were transferred
electrically to a PVDF membrane and incubated with the
following antibodies; anti-TNF-a, anti-IL1b (Cell Signaling
Technology, Inc., Beverly, MA, USA), anti-DMT1, anti-hepci-
dine25, anti-CPT1A, anti-CPT2, anti-SOD2, anti-catalase (Ab-
cam, Tokyo, Japan), anti-GPx4 (LifeSpan BioSciences, Seattle,
WA, USA). Membranes were washed and incubated with
respective secondary antibodies. Detection of bands was per-
formed by chemiluminescent analysis. Beta actin was used as a
loading control. Representative data of three experiments were
shown on figures.
Hepatic 8-hydroxydeoxyguanosine (8-OHdG)
concentration analysis
8-OHdG, a modified DNA base product generated by free
radicals, is a biomarker of oxidative DNA damage [15]. DNA was
extracted from the liver using a DNA extractor kit (DNA Extractor
TIS Kit; Wako, Osaka, Japan). Hepatic 8-OHdG concentration
was measured by using an enzyme-linked immunosorbent assay kit
(Highly sensitive 8-OHdG Check; Japan Institute for the Control
of Aging, Shizuoka, Japan) after preparation with an exclusive kit
(8-OHdG Assay Preparation Reagent Set; Wako). Results were
expressed as ng/mg DNA corrected against the DNA level in each
sample.
Metabolomic analysis
For metabolomic analysis, control C57BL/6 mice fed a
standard diet and STAM mice were compared. Eight-week-old
male C57BL/6 mice were fed standard chow for 4 weeks as the
BL6-Control group. The three experimental groups were STAM
mice fed a HFD (control group); STAM mice fed a HFD mixed
with 0.28% L-carnitine (L-carnitine group); and STAM mice fed a
HFD mixed with 0.01% a-tocopherol (a-tocopherol group). After
4 weeks, liver tissue was harvested and immediately frozen in a 2
80uC freezer. The capillary electrophoresis time-of-flight mass
spectrometry (CE-TOFMS)–based metabolome analysis was
performed at Human Metabolome Technologies (Yamagata,
Japan). Metabolites in the samples were identified by comparing
the migration time and m/z ratio with authentic standards and
quantified by comparing their peak areas with those of authentic
standards.
Intestinal microbiome analysis
Analysis of intestinal bacterial flora by using fecal specimens was
conducted by TechnoSuruga Laboratory (Shizuoka, Japan) with
the terminal restriction fragment length polymorphism method
[16]. In brief, frozen fecal specimens were suspended, and DNA
was extracted.
Figure 3. Assessment of oxidative stress and inflammation in the liver. (A) Concentrations of 8-OHdG in the liver. (B) Representative
immunohistochemical staining for 4-HNE in STAM mouse liver tissue. The intensity of 4-HNE was calculated by computerized image analysis with
Olympus cellSens imaging software. (C) Results of quantitative real-time PCR assay to detect TNF-a and IL-1b mRNA levels are shown. (D) Western
blotting analysis of the hepatic extracts was performed with each antibodies. Data are expressed as means 6 SD. *P,0.05. 8-OHdG, 8-hydroxy-
deoxyguanosine; 4-HNE, 4-hydroxynonenal; TNF-a, tumor necrosis factor alpha; IL-1b, interleukin-1b.
doi:10.1371/journal.pone.0100627.g003
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PCR was performed using total fecal DNA and primers of
Escherichia coli positions 516 to 532 and positions 1510 to 1492. The
resulting 16S rDNA amplicons were treated with Bsl l, and
digested products were fractionated using an automated sequence
analyzer in the DNA analysis software Gene Mapper. Because the
apparent size of identical terminal restriction fragments can vary
over a range of 1–3 bp, major fragments similar in size to 1–3 bp
were summarized to operational taxonomic units.
Statistical analysis
Results are expressed as means 6 standard deviation for
parametric data and medians for non-parametric data. All
parametric data were compared using the Tukey method, and
non-parametric data were compared by the Steel-Dwass method.
Data were considered to be statistically significant at P,0.05.
Results
Body weight and biochemical analysis
There were no significant differences in body weight among the
three groups (Fig. 1A). Fasting blood glucose levels were very high
because pancreatic beta cells were destroyed by the streptozotocin
treatment in this model (Fig. 1B). Serum alanine aminotransferase
levels were slightly lower in the L-carnitine and a-tocopherol
groups, serum and hepatic triglyceride levels were slightly lower in
the treatment groups, although neither of these differences was
statistically significant (Fig. 1C).
L-carnitine and a-tocopherol resulted in improved NASH
histology
As shown in Figure 2A, the control group developed hepatocyte
steatosis, ballooning, and scattered inflammatory cell infiltration at
12 weeks. Hepatocyte steatosis was clearly reduced in the L-
carnitine group at 12 weeks, and hepatocyte ballooning was clearly
reduced in the a-tocopherol group at 12 weeks. NAFLD activity
score was significantly lower in the L-carnitine and a-tocopherol
groups (Fig. 2B).
L-carnitine Induced strong reduction of oxidative stress
in liver
The concentration of 8-OHdG in the liver was significantly
reduced in the L-carnitine and a-tocopherol groups (Fig. 3A). The
immunohistochemical staining intensity of 4-HNE was significant-
ly decreased in the L-carnitine group (Fig. 3B), and mRNA levels
of TNF-a, but not IL-1b, were significantly down-regulated in the
L-carnitine group (Fig. 3C). The protein expression levels
examined with Western blot analysis indicated the same pattern
(Fig. 3D).
Figure 4. Quantitative real-time PCR results and Western blotting results for expression of hepatic mitochondrial pathway-related
genes. (A) mRNA levels of L-carnitine transport-related gene OCTN-2 and long chain fatty acid transport-related genes Cpt1a and Cpt2 were
analyzed. (B) mRNA levels of mitochondrial b-oxidation-related gene MCAD were measured. (C) mRNA levels of antioxidant system-related genes
Sod2, CAT, and Gpx1 were analyzed. Data are expressed as means 6 SD. (D) Western blotting was performed with the following antibodies directed
to Cpt1a, Cpt2, Sod2, CAT and Gpx4. b-actin was used as a loading control. *P,0.05. OCTN, organic cation/carnitine transporter; Cpt, carnitine
palmitoyltransferase; MCAD, medium chain acyl CoA dehydrogenase; Sod, superoxide dismutase; CAT, catalase; Gpx, glutathione peroxidase.
doi:10.1371/journal.pone.0100627.g004
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Table 1. Metabolomic analysis (Control/BL6-Control).
Pathway Metabolite Control vs. BL6 control
Ratio" p-value||
b-Alanine metabolism 3-Ureidopropionic acid 4.4 0.003 **
ATP-binding cassette (ABC) transporter Putrescine 4.6 0.011 *
Folate biosynthesis 5,6,7,8-Tetrahydrobiopterin 3.9 0.004 **
Citrate cycle (TCA cycle) Malic acid 2.8 0.018 *
Inositol phosphate metabolism myo-Inositol 1-phosphate 2.2 0.004 **
Inositol phosphate metabolism myo-Inositol 3-phosphate 2.2 0.004 **
Nicotinate and nicotinamide metabolism 1-Methylnicotinamide 2.2 0.028 *
b-Alanine metabolism b-Alanyl-L-lysine
(b-Ala-Lys)
2.1 0.018 *
Butanoate metabolism 2-Hydroxyglutaric acid 1.8 0.043 *
Ascorbate and aldarate metabolism Ascorbic acid 1.9 0.028 *
ATP-binding cassette (ABC) transporter Glutamate 1.8 0.006 **
ATP-binding cassette (ABC) transporter Glutathione (GSH) 1.5 0.020 *
Glutathione metabolism c-glutamylcysteine (c-Glu-Cys) 1.5 0.047 *
Ascorbic acid and aldaric acid metabolism Threonic acid 1.4 0.016 *
Glycerophospholipid metabolism Ethanolamine phosphate 1.4 0.025 *
ATP-binding cassette (ABC) transporter Aspartic acid 1.4 0.029 *
Synthesis and degradation of ketone bodies 3-Hydroxybutyric acid 1.4 0.040 *
Citrate cycle (TCA cycle) Succinic acid 1.3 0.015 *
ATP-binding cassette (ABC) transporter Lysine 0.7 0.001 ***
Ascorbic acid and aldaric acid metabolism Ribulose 5-phosphate 0.7 0.002 **
Nicotinate and nicotinamide metabolism Nicotinamide 0.7 0.001 ***
ATP-binding cassette (ABC) transporter Leucine 0.7 0.007 **
Urea cycle Creatinine 0.7 0.007 **
Glycine, serine and threonine metabolism Homoserine 0.7 0.014 *
ATP-binding cassette (ABC) transporter Valine 0.7 0.032 *
Zeatin biosynthesis 59-Deoxy-59
-methylthioadenosine
0.7 0.044 *
Amino sugar and nucleotide sugar metabolism Glucose 6-phosphate 0.7 0.047 *
ATP-binding cassette (ABC) transporter Isoleucine 0.6 0.000 ***
Purine metabolism Inosine 0.6 0.005 **
Urea cycle Ornithine 0.6 0.005 **
Glycine, serine and threonine metabolism N,N-Dimethylglycine 0.6 0.009 **
Cysteine metabolism Glutathione (GSSG)_divalent 0.6 0.011 *
Glutathione metabolism NADP+ 0.6 0.011 *
ATP-binding cassette (ABC) transporter Glycerol 3-phosphate 0.6 0.011 *
ATP-binding cassette (ABC) transporter Threonine 0.6 0.013 *
Pyrimidine metabolism Thymidine 0.6 0.016 *
Pyrimidine metabolism Cytidine monophosphate (CMP) 0.6 0.042 *
ATP-binding cassette (ABC) transporter Thiamine 0.6 0.043 *
ATP-binding cassette (ABC) transporter Glycine 0.5 0.000 ***
Thiamine metabolism Thiamine phosphate 0.5 0.000 ***
Purine metabolism Guanosine 0.5 0.009 **
b-Alanine metabolism b-Alanine 0.5 0.010 *
b-Alanine metabolism Carnosine 0.5 0.014 *
Histidine metabolism 3-Methylhistidine 0.5 0.027 *
Purine metabolism ADP-ribose 0.5 0.034 *
Lysine degradation c-Butyrobetaine 0.4 0.000 ***
Pyruvate metabolism Phosphoenolpyruvic acid 0.4 0.000 ***
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L-carnitine and a-tocopherol upregulated mitochondrial
transport-related and antioxidant defensive system-
related gene expression in liver
mRNA levels of the L-carnitine transport-related gene OCTN2
were significantly up-regulated in the L-carnitine and a-tocopherol
groups. mRNA levels of LCFAs transport-related gene Cpt1a were
significantly up-regulated in the L-carnitine and a-tocopherol
groups, and Cpt2 was significantly up-regulated in the L-carnitine
group (Fig. 4A). mRNA levels of mitochondrial b-oxidation-
related gene MCAD were significantly up-regulated in the L-
carnitine and a-tocopherol groups (Fig. 4B).
mRNA levels of Sod2 were significantly up-regulated in the L-
carnitine and a-tocopherol groups. mRNA levels of CAT were
significantly up-regulated in the L-carnitine group, and mRNA
levels of Gpx4 were significantly up-regulated in the a-tocopherol
group (Fig. 4C). The protein expression levels examined with
Western blot analysis indicated the same pattern (Fig. 4D).
a-tocopherol resulted in iron transport-related DMT-1
gene expression in liver
The immunohistochemical staining intensity of ferritin was
significantly increased in the a-tocopherol group (Fig. 5A). mRNA
levels of DMT-1 were significantly up-regulated in the a-
tocopherol group. mRNA levels of Hamp (hepcidin) were not
significantly different among the three groups (Fig. 5B). We next
examined the protein expression levels of them using Western blot
analysis indicating the same pattern.
L-carnitine resulted in increased mitochondrial function-
related metabolites in NASH
When compared with the BL6-control group, levels of 38
metabolites were significantly higher, and levels of 18 metabolites
were significantly decreased in the control group (Table 1). When
compared with the control group, levels of carnitine were
significantly higher in the L-carnitine group. Levels of several
metabolites related to the tricarboxylic acid cycle, urea cycle, and
antioxidant pathway were increased in the L-carnitine group when
compared with the control group. In the a-tocopherol group,
several antioxidant- and urea cycle-related metabolites were also
significantly higher, although to a lesser extent than in the L-
carnitine group (Table 2).
a-tocopherol induced intestinal microbiome changes
The intestinal bacterial flora in the NASH model mice was
characterized by less Lactobacillales and more Prevotella than in
healthy controls (Fig. 6A). These differences were more evident in
the a-tocopherol group but less evident in the L-carnitine group.
L-carnitine reduced hepatic tumorigenesis
Liver tumors were found in all mice in each STAM group at 16
weeks (Fig. 7A). Histological findings showed that the tumors were
HCC (Fig. 7B). The L-carnitine group developed fewer tumors.
There were no significant differences in tumor size among the
three groups (Fig. 7C).
Discussion
The present results confirmed that L-carnitine increased hepatic
expression of genes related to LCFAs transport, mitochondrial b-
oxidation, and antioxidant enzymes following suppression of
hepatic oxidative stress markers and inflammatory cytokines in
NASH. Furthermore, L-carnitine reduced NASH-related hepatic
tumorigenesis in mouse models. a-tocopherol resulted in NASH
improvement in the same manner. However, it increased
periodontitis-related microbiotic change and hepatic iron trans-
port-related gene expression, and ultimately led to more severe
hepatocarcinogenesis. These results indicate that L-carnitine
represents a simple and novel therapeutic strategy for NASH.
Numerous drugs have been tested for the potential to alleviate
fatty liver and NASH. These treatments have diverse pharmaco-
logical activities such as improvement of insulin sensitivity,
stimulation of lipid oxidation, as well as reduction of de novo
lipogenesis, oxidative stress, and inflammation that are character-
istics of NASH [17]. Among these drugs, the antioxidant drug
vitamin E is the first-line treatment recommendation for NASH.
ROS are widely accepted as a source of oxidative stress that
appears to be responsible for the initiation of necroinflammation.
ROS are generated during the metabolism of free fatty acids in
microsomes, peroxisomes, and particularly in mitochondria. Most
of the electrons provided to the mitochondrial respiratory chain
migrate along this chain to finally reach cytochrome c oxidase,
where they safely combine with oxygen and protons to form water
[18]. However, some of these electrons leak to form the superoxide
anion radical. This radical can then be dismutated by Sod2 into
hydrogen peroxide, which is normally detoxified into water by
Table 1. Cont.
Pathway Metabolite Control vs. BL6 control
Ratio" p-value||
Glycine, serine and threonine metabolism Betaine aldehyde_+H2O 0.4 0.001 **
b-Alanine metabolism Gamma-aminobutyric acid (GABA) 0.4 0.003 **
Purine metabolism Guanine 0.4 0.004 **
Pyrimidine metabolism Cytidine 0.4 0.006 **
ATP-binding cassette (ABC) transporter Serine 0.4 0.007 **
Glyoxylate and dicarboxylate metabolism 3-Phosphoglyceric acid 0.4 0.008 **
Glycerophospholipid metabolism Phosphorylcholine 0.3 0.015 *
Arginine and proline metabolism 5-Aminovaleric acid 0.2 0.003 **
Histidine metabolism Ergothioneine 0.0 0.024 *
"; ratio of left divided by right.
||; p-value: ***p,0.001, **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0100627.t001
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Gpxs and CAT [19]. Thus, most mitochondrial ROS are usually
detoxified, and residual ROS serve as signaling molecules.
Physiologically low levels of ROS are involved in necessary vital
cellular processes, indicating that an adequate control of oxidative
stress and balance of oxidative and anti-oxidative responses is
important [20]. Excess superoxide could be generated within
injured mitochondria through electron leakage, and the resulting
excess of superoxide would be converted to hydrogen peroxide by
Sod2. Gpxs or CAT can metabolize hydrogen peroxide to non-
toxic H2O, but the Fenton and/or Haber-Weiss reactions
mediated by iron generate highly reactive toxic ROS, hydroxyl
radicals. Levels of iron are elevated in NASH, which is an inducer
of oxidative stress, and reduced iron levels result in fair outcomes
for patients with chronic liver diseases [21].
L-carnitine supplementation in NASH patients greatly im-
proved glucose plasma levels, lipid profiles, and histological
manifestations [22]. Furthermore, L-carnitine ameliorated fatty
liver in high-calorie diet/streptozotocin-induced type 2 diabetic
mice by improving mitochondrial function [23]. We assumed that
L-carnitine may alter not only the LCFA uptake into mitochon-
dria, but also the activity of the ROS-scavenging antioxidant
enzymes in NASH model mice. The present data showed that L-
carnitine reinforced the mitochondrial b-oxidation and the activity
of the key ROS-scavenging antioxidant enzymes such as Sod2 and
CAT without an increase in oxidative stress. In addition, L-
carnitine has recently been shown to exhibit ammonia reduction
in hepatic encephalopathy patients and improvement of fatigue,
which reflects the wide pharmacological effects of L-carnitine on
hepatic and muscular mitochondrial function recovery [24]. We
were not able to demonstrate such effects of L-carnitine in our
model, as we did not examine plasma ammonia levels or physical
scores that reflect hepatic encephalopathy and related effects.
The role of a-tocopherol in the treatment of NASH is based on
its activity as a free-radical scavenger. a-tocopherol is a chain-
breaking antioxidant in free-radical reactions, which is an
important step in lipid peroxidation and membrane stabilization
[25]. Animal studies have shown that a-tocopherol improves
fibrosis, reduces mitochondrial lipid peroxidation, and corrects
oxidative stress in animal models of liver disease associated with
oxidative injury [26]. However, the life-long administration of a-
tocopherol to animals exposed to cold or warm stress resulted in a
significantly shortened life span [27]. In humans, several
randomized controlled trials have indicated a potential role for
vitamin E supplementation in NAFLD [28,29]. These studies
included biochemical data and liver histological assessment, but
they lasted for only several years. Many cerebrovascular disease
studies have investigated the effects of vitamin E. A meta-analysis
of the effect of vitamin E on stroke revealed a 10% reduction in
ischemic stroke accompanied by a 22% increase in hemorrhagic
stroke [30]. Furthermore, meta-analysis revealed that all-cause
mortality with vitamin E and vitamin A supplementation was
worse than for controls [31]. Our data showed that a-tocopherol
increased mitochondrial b-oxidation-related enzyme gene expres-
sion without increased oxidative stress or altered activity of key
ROS-scavenging antioxidant enzymes such as Sod2 and Gpx4.
Overall, the trend was stronger in the L-carnitine group, with the
exception that the expression of the iron transport-related gene
Figure 5. Iron metabolism related pathway analysis. (A) Representative immunohistochemical staining for ferritin of STAM mouse liver tissue.
Intensity of ferritin was calculated by computerized image analysis using Olympus cellSens imaging software. (B) mRNA levels of iron uptake-related
hepcidin coding gene Hamp and iron transport-related gene DMT-1 were analyzed. Data are expressed as means 6 SD. (C) Liver extracted proteins
were analyzed with Western blotting with antibodies directed to DMT-1 and Hamp (hepcidine). *P,0.05. DMT, divalent metal transporter; Hamp,
hepcidin coding gene.
doi:10.1371/journal.pone.0100627.g005
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DMT-1 was higher in the a-tocopherol group than in the L-
carnitine group.
Iron is an essential metal for all organisms and plays a crucial
role in a variety of cellular functions in metabolism, growth, and
differentiation, such as oxygen transport and storage, energy
production, cell cycle, and DNA synthesis [32]. However, excess
cellular iron is toxic, resulting in hydroxyl radical production via
the Fenton reaction. Ferritin is an important hub for iron
metabolism. Ferritin sequesters iron during conditions of iron
excess and releases iron during conditions of iron scarcity [33]. In
the present study, intrahepatic ferritin was expressed at higher
levels in the a-tocopherol group than in the L-carnitine group,
while the expression of important iron metabolism-related genes
such as hepcidin showed no difference. These results suggest that
the higher expression of ferritin in the a-tocopherol group was not
due to simple iron load but that oxidative stress or inflammatory
cytokines induced ferritin expression. In human cirrhotic livers,
DMT-1 and ferritin mRNA are more highly expressed than in
control donor livers, possibly due to an inflammatory or stress-
responsive pathway, while hepcidin expression showed no
difference [34]. While the exact mechanism of why such
differences are seen in human cirrhosis is unknown, cirrhotic
conditions in the liver might induce changes in iron metabolism.
As inflammatory cytokines such as interleukin-1b showed no
difference between the two drug groups in our model, an aberrant
oxidative stress condition between these two drugs might be an
important issue.
NASH is an accepted risk factor for hepatic carcinogenesis, but
the precise mechanism contributing to hepatocarcinogenesis
remains unclear. Gut microbiota changes are involved in NASH
progression [35]. Recently, obesity-induced gut microbiota
changes such as Bacteroides reduction have been shown to increase
the levels of deoxycholic acid, a gut bacterial metabolite that
causes DNA damage resulting in increased incidence of hepato-
cellular carcinoma [36]. In our non-obese NASH model, Prevotella
(Bacteroides) proliferated more than normal controls, while it has
been accepted to be less common in obesity patients. Prevotella is
correlated with periodontal diseases or upper respiratory tract
infection. In our present results, a-tocopherol showed the strongest
effect on benign Lactobacillus reduction and Prevotella (Bacteroides)
proliferation, which might be one reason for the unfavorable
outcome.
Oxidative stress has been shown to be involved in hepatocar-
cinogenesis with telomerase activation or increased neovascular-
ization [37,38]. One oxidative stress marker, 8-OHdG, is
increased in NASH-related hepatocellular carcinoma patients
[39]. Current human therapeutic drug trials on NASH revealed
only short-term improvement in laboratory data and NASH
histology but no data in the long-term outcome of hepatocarcin-
ogenesis or mortality. NASH mouse models developing HCC
must be a good marker to reveal the long-term effect of treatments.
The STAM NASH model is a promising model to show NASH-
related hepatocarcinogenesis, but lean body with low adipose fat
and low insulin levels exhibits a different course than human
NASH hepatocarcinogenesis. There are several diabetic or obesity
models that exhibit NAFL or NASH, but typically show a low
incidence of HCC. We believe that such models reflect only NAFL
or non-advancing NASH, which are not treatment targets; thus we
selected this model in our experiments. The hepatic tumor
number was reduced in the L-carnitine group. Differences
Figure 6. Intestinal microbiome analysis. (A) The 100% stacked column chart of microbiome from intestinal feces. (B) Representative
percentages of bacterial species in experimental groups. *P,0.05.
doi:10.1371/journal.pone.0100627.g006
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between the L-carnitine and a-tocopherol groups, such as 4-HNE
expression, iron transport-related DMT-1 gene expression, mito-
chondrial pathway-related metabolomics profiles, and intestinal
microbiome patterns might be involved in anti-hepatocarcinogen-
esis mechanisms. Oxidative stress is accepted as carcinogenic, but
antioxidant treatment has been shown to exacerbate cancers.
Antioxidants might permit cancer cells to transform into the stem
cell-like cancer cells that have powerful antioxidative properties
and are thus anti-apoptotic [40]. L-carnitine has histone
deacetylase-inhibiting potential and thus shows anti-tumor activity
against HCC cell lines and mouse models, which might be one
reason for the better outcome of the L-carnitine group [41].
In conclusion, we confirmed that L-carnitine improves the
hepatic expression of genes related to LCFAs transport, mito-
chondrial b-oxidation, and metabolites following decreased
oxidative stress. Furthermore, L-carnitine improves NASH-related
hepatocarcinogenesis in a mouse model. These results indicate
that the mitochondrial function modifier L-carnitine provides a
simple and novel therapeutic strategy for NASH.
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